How We Score Safety Clarity

We assess safety on multiple dimensions: extent of safety testing (animal studies, human trials), documentation of adverse events (are they reported systematically?), transparency about unknowns (is uncertainty acknowledged?), and accessibility of safety information (is it easy to find comprehensive safety data?).

We assess how much safety data is available. A peptide with extensive human trial data showing good safety is clearer than a peptide with only animal data. Absence of safety data creates uncertainty.

We distinguish between 'no adverse events reported' (lack of reporting) and 'no adverse events observed' (confirmed absence).

We assess the quality of adverse-event reporting: are events documented systematically in formal trials? Are severity and causality assessed? Are there reporting biases? Data from rigorous clinical trials is higher quality than spontaneous adverse-event reports.

We assess whether safety has been studied in relevant populations. A peptide studied only in healthy young men has unclear safety in other populations. Diverse populations strengthen safety clarity.

We assign a safety clarity rating: Clear (comprehensive safety data with documented adverse events), Moderate (some safety data but gaps remain), Limited (minimal human safety data), or Unclear (very limited data or significant gaps). These ratings reflect the state of safety knowledge, not whether adverse events exist.

A rating of 'Limited' or 'Unclear' safety does not mean the peptide is unsafe. It means safety is not well-characterized. Absence of evidence is different from evidence of absence.